Download Publications: Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS

Publications:
1. Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL, Clinical
Activity of Afatinib in Advanced NSCLC Harbouring Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations: Combined Analysis of
LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncology 2015 July;16(7): 830–838
2. Yang JC*, Wu YL*, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O’Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM,
Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V and Sequist LV. Afatinib versus
cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data
from two randomised, phase 3 trials Lancet Oncology 2015 Feb;16(2):141-51. (*corresponding author)
3. Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam S, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, EFelip E, Kim JH, Frewer P, Cantarini M,
Brown K, Dicknson P, Giorghiu S and Ranson M. AZD9291 in EGFR TKI resistant nonsmall cell lung cancer. New England Journal of Medicine
2015;372:1689-1699
4. Lee CH, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla RJ, Yang JC*. The impact of specific
EGFR mutations and clinical characteristics on outcomes from EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR mutant lung cancer – a
meta-analysis. Journal of Clinical Oncology 2015 Jun 10;33(17):1958-65 (*corresponding author)
5. Soria JC, Wu YL, Nakagawa K Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagai S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A,
Jiang H and Mok TS. Gefitinib/chemotherapy versus chemotherapy in EGFR mutation-positive NSCLC after progression on first-line gefitinib : the phase III
randomized IMPRESS study. Lancet Oncology 2015 Aug;16(8):990-8.
6. Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, Ho CC, Shih JY, Yu CJ, Yang JC*. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small
cell lung cancer patients with leptomeningeal carcinomatosis. J Thorac Oncol. 2015 Sep 2. [Epub ahead of print] (corresponding author)
7. Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL, Hsia TC, Wu MF, Lai CL, Lee KY, Lin CB, Yu-Wung Yeh D,
Chuang CY, Chang FK, Tsai CM, Perng RP, Chih-Hsin Yang J. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced
Lung Adenocarcinomas with G719X/L861Q/S768I Mutations J Thorac Oncol. 2015 May;10(5):793-9
8. Yang JC*, Sequist LV. Reply to E.R. Haspinger et al. J Clin Oncol. 2014 Mar 10;32(8):863-4 (*Corresponding author)
9. Yang JC*, Sequist LV. Reply to F. de Marinis et al. J Clin Oncol. 2014 Mar 10;32(8):865. (*Corresponding author)
10. Yang JC, Kang JH, Mok T, Ahn MJ, Srimuninnimit V, Lin CC, Kim DW, Tsai CM, Barraclough H, Altug S, Orlando M, Park K. First-line pemetrexed plus
cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous
non-small cell lung cancer: a randomised, phase 3 trial. Eur J Cancer. 2014 Sep;50(13):2219-30
11. Yang JC*, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R, Mok TS. Epidermal growth factor receptor mutation
analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer. 2014
Feb;83(2):174-81. (*Corresponding author)
12. Yang JC*, Hirsh V, Schuler M, Yamamoto N, O’Byrne K, Mok T, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom
Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Advanced Lung Adenocarcinoma Patients With Epidermal
Growth Factor Receptor Mutations. Journal of Clinical Oncology 2013 Sep 20;31(27):3342-3350 (*corresponding author)
13. Sequist LV, Yang JC*, Yamamoto N, O”Byrne K, Hirsh V, Mok T, Geater SL, Pavlov SO, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee
KH, Shah R, Massey D, Zazulina V, Shahidi M and Schuler M. Phase III study of Afatinib or Cisplatin/Pemetrexed in Metastatic Lung Adenocarcinoma Patients
with Epidermal Growth Factor Receptor Mutations. Journal of Clinical Oncology 2013 Sep 20;31(27):3327-3334 (*Corresponding author and equal
contribution with first author).
14. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu DT, Zaatar A, Sanchez J, Vu VV, Au JS, Inoue A, Lee SM, Gebski V,
Yang JC*. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis Journal of The National Cancer
Institute 2013 May 1;105(9):595-605 (*Corresponding author)
15. Yang JC. A selective ALK inhibitor in ALK-rearranged patients. Lancet Oncology 2013 Jun; 14 (7) 564-565 (comments)
16. Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin MY, Yang JC*. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung
cancer cells with acquired resistance to gefitinib. Molecular Oncology 2013 Feb; 7:112-120
(*corresponding author)
17. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller
VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012
May;13(5):539-48.
18. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ,
Lorence RM, Yang JC*. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both,
and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012 May;13(5):528-38. (*corresponding author)
19. Medema RH, Lin CC, Yang JC*. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin Cancer Res. 2011
Oct 15;17(20):6459-66. (*corresponding author) (Review article)
20. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Da-Tong Chu, Saijo N, Duffield E, Rukazenkov Y,
Speake G, Jiang H, Armour A, To KF, Yang JC, Mok T. Biomarker Analyses and Final Overall Survival Results from a Phase III, Randomized, Open-Label,
First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients with Advanced Non-Small-Cell Lung Cancer in Asia (IPASS) J Clin
Oncol 2011 Jul 20;29(21):2866-74.
21. Salto-Tellez M, Tsao MS, Shih JY, Thongprasert S, Lu S, Chang GC, Au JS, Chou TY, Lee JS, Shi YK, Badruddin RA, Kang JH, Kim SW, Tan SY, Yang JC*
Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations in East Asian Non-Small Cell Lung Cancer (NSCLC)
Patients – A Combined Clinical-Molecular Pathological Approach. J Thorac Oncol 2011 Oct; 6(10): 1663-1669 (*Corresponding author)
22. Yang CH, Simms L, Park K, Lee JS, Scagliotti G, Orlando M. Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line
Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer. Results of an Exploratory Subgroup Analysis of a Phase III Trial. Journal of
Thoracic Oncology 2010 May;5(5):688-695
Other pertinent publications
23. Liao BC, Lin CC, Shih JY, Yang JC. Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv
Med Oncol. 2015 Sep;7(5):274-90. (review)
24. Tang MC, Wu MY, Hwang MH, Chang YT, Huang HJ, Lin AMY*, Yang JC*. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell
lung cancer cells. PLOS one 2015 Mar 25;10(3):e0119135 (* Corresponding author)
25. Liao BC, Lin CC, Yang JC*. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
Current Opin Oncol 2015 March ;27(2):94-101 (*corresponding author) (review)
26. Liu YN, Chang TH, Tsai MF, Wu SG, Tsai TH, Chen HY, Yu SL, Yang JC and Shih JY. IL-8 Confers Resistance to EGFR Inhibitors by Inducing Stem Cell
Properties in Lung Cancer Oncotarget 2015 Apr 30;6(12):10415-31
27. Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. Liao BC, Shao YY, Chen HM,
Shau WY, Lin ZZ, Kuo RN, Lai CL, Chen KH, Cheng AL, Yang JC, Lai MS. Clin Lung Cancer. 2015 Mar;16(2):137-43. (*Corresponding author)
28. Lu WC, Lin CC, Yang JC. Angiokinase inhibitors in non-small cell lung cancer. Clinical Investigation 2015 5(1),47-59 (review)
29. Liao BC, Shao YY, Chen HM, Shau WY, Lin ZZ, Kuo RN, Lai CL, Chen KH, Cheng AL, Yang JC*, Lai MS. Comparative effectiveness of first-line
platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. Clin Lung Cancer. 2015 Mar;16(2):137-43. (*Corresponding author)
30. Tsai TH, Wu SG, Hsieh MS, Yu CJ, Yang JC, Shih JY. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma
patients with malignant pleural effusion. Lung Cancer. 2015 Mar 4. pii: S0169-5002(15)00151-8
31. Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, Wang YW, Yeh CG, Chiang NJ, Chang JY, Chen LT. Phase I study of nanoliposomal
irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015 Mar;75(3):579-86.
32. Yang JC, Ahn MJ, Nakagawa K, Tamura T, Barraclough H, Enatsu S, Cheng R, Orlando M. Pemetrexed Continuation Maintenance in Patients with
Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT. Cancer Res Treat. 2014 Sep 15.
33. Chen YF, Hsieh MS, Wu SG, Chang YL, Shih JY, Liu YN, Tsai MF, Tsai TH, Yu CJ, Yang JC, Yang PC. Clinical and the prognostic characteristics of lung
adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. J Thorac Oncol. 2014 Aug;9(8):1171-9
34. Lin YT, Wang YF, Yang JC, Yu CJ, Wu SG, Shih JY, Yang PC. Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive
Non-Small-Cell Lung Cancer. J Thorac Oncol. 2014 Nov;9(11):1720-1725
35. Hsu CL, Chen JH, Chen KY, Shih JY, Yang JC, Yu CJ, Yang PC. Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on
treatment modalities and patient prognosis. J Geriatr Oncol. 2015 Jan;6(1):38-45
36. Lee JH, Lin YL, Hsu WH, Chen HY, Chang YC, Yu CJ, Shih JY, Lin CC, Chen KY, Ho CC, Laio WY, Yang PC, Yang JC*.Bcl-2-Like Protein 11 Deletion
Polymorphism Predicts Survival in Advanced Non-Small-Cell Lung Cancer. J Thorac Oncol. 2014 Sep;9(9):1385-92. (*Corresponding author)
37. Lin CC, Su WC, Yen CJ, Hsu CH, Su WP, Yeh KH, Lu YS, Cheng AL, Huang DC, Fritsch H, Voss F, Taube T, Yang JC*. A phase I study of two dosing
schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer. 2014 May
13;110(10):2434-40. (*Corresponding author)
38. Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Marsland T, Patel T, Rubin M, White L, Yang JC, Klughammer B, Colburn D, Miller V,
Johnson BE.Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance
Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS). J Thorac Oncol. 2014 Sep;9(9):1411-7.
39. Popat S, Mok T, Yang JC, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L. Afatinib in the treatment of EGFR
mutation-positive NSCLC - A network meta-analysis. Lung Cancer. 2014 Aug;85(2):230-8.
40. Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. Treatment of Advanced
Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert
Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2014 May;15(3):173-81.
41. Ghamande S, Lin CC, Cho DC, Shapiro GI, Kwak EL, Silverman MH, Tseng Y, Kuo MW, Mach WB, Hsu SC, Coleman T, Yang JC, Cheng AL, Ghalib MH,
Chuadhary I, Goel S. A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388
administered to patients with advanced solid tumors. Invest New Drugs. Invest New Drugs. 2014 Jun;32(3):445-51
42. Kao HF, Chen IC, Hsu C, Chang SY, Chien SF, Chen YC, Hu FC, Yang JC, Cheng AL, Yeh KH. Chlorhexidine for the prevention of blood stream infection
associated with totally implantable venous ports in patients with solid cancers. Support Care Cancer. 2014 May;22(5):1189-97.
43. Interview of James Chih-Hsin Yang, Changing advanced lung cancer into chronic disease. Lung Cancer Management 2014;3(1),1-5
44. Lin ZZ, Shau WY, Hsu C, Shao YY, Yeh YC, Kuo RN, Hsu CH, Yang JC, Cheng AL, Lai MS. Radiofrequency ablation is superior to ethanol injection in
early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One 2013 Nov 11;8(11):280276
45. Kao HF, Lin CC, Yang JC*. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Future Oncol. 2013
Jul;9(7):991-1003 (*corresponding author) (review article)
46. Wu PF, Huang WC, Yang JC, Lu YS, Shih JY, Wu SG, Lin CH, Cheng AL. Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic
factor in brain metastases from lung adenocarcinomas. J Neurooncol. 2013 Oct;115(1):61-70
47. Wu YL, Fukuoka M, Mok TS, Saijo N, Thongprasert S, Yang JC, Chu DT, Yang JJ, Rukazenkov Y. Tumor response and health-related quality of life in
clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study. Lung
Cancer 2013 Aug;81(2):280-7
48. Johnson B, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden
C, and Miller V. ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After
Completion of Chemotherapy With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) J Clin Oncol. 2013 Nov
1;31(31):3926-34.
49. Shao YY, Shau WY, Lin ZZ, Chen HM, Kuo R, Yang JC*, Lai MS*. Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced
non-small-cell lung cancer. Eur J Cancer. 2013 Jan;49(1):106-14. (*Co-corresponding authors)
50. Yang JC*, Reguart N, Barinoff J, Köhler J, Uttenreuther-Fischer M, Stammberger U, O’Brien D, Wolf J, Cohen E. Diarrhea associated with afatinib, an oral
ErbB family blocker. Expert review of Anticancer Therapy 2013 Jun;13(6):729-36.
(*corresponding author) (review)
51. Chang GC, Tsai CM, Hsia TC, Yang CH, Abdulnabi R, Blair JM, Linn C. Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell
lung cancer:An open-label single-arm study. J. Formosan Med Asso 2013 Sep ; 112;518-526
52. Liao BC, Lin CC, Yang JC. First-Line Management of Egfr-Mutated Advanced Lung Adenocarcinoma: Recent Developments. Drugs. 2013 Mar;73(4):357-69.
(review)
53. Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M, Yang JC. Symptom and quality of life benefit of afatinib in
advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac
Oncol. 2013 Feb;8(2):229-37
54. Liao WY, Chen JH, Wu M, Shih JY, Chen KY, Ho CC, Yang JC, Yu CJ. Neoadjuvant Chemotherapy With Docetaxel-Cisplatin in Patients With Stage III N2
Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2013 Jul;14(4):418-24
55. Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, Lai HH, Lin TY, Yang JC, Yang PC, Shih JY, Lin SB. ALDH-positive lung cancer stem cells confer
resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 2013 Jan 1;328(1):144-51.
56. Lee YC, Lee LM, Yang CH, Lin AM, Huang YC, Hsu CC, Chen MS, Chi CW, Yin PH, Kuo CD, Liao JF, Lee HC. Norcantharidin suppresses cell growth and
migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells. Oncol Rep. 2013 Jan;29(1):237-43.
57. Wu SG, Yu CJ, Tsai MF, Liao WY, Yang CH, Jan IS, Yang PC, Shih JY. Survival of lung adenocarcinoma patients with malignant pleural effusion. Eur Respir
J. 2013 Jun;41(6):1409-18
58. Tsai TH, Yang CY, Ho CC, Liao WY, Jan IS, Chen KY, Wang JY, Ruan SY, Yu CJ, Yang JC, Yang PC, Shih JY. Multi-gene analyses from waste brushing
specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. Lung Cancer. 2013 Dec;82(3):420-5
59. Chang YC, Yu CJ, Chen CM, Hu FC, Hsu HH, Tseng WY, Ting-Fang Shih T, Yang PC, Yang JC* Dynamic contrast-enhanced MRI in advanced nonsmall-cell
lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. J Magn Reson Imaging. 2012 Aug;36(2):387-96. (corresponding author)
60. Yang JC. Small-Cell Lung Cancer Treatment: Where is the Target? J Thorac Oncol. 2012 Sep;7(9):1327-8. (editorial)
61. Lin ZZ, Shau WY, Shao YY, Yang YY, Kuo RN, Yang JC*, Lai MS. Survival Following Surgery with or without Adjuvant Chemotherapy for Stage I-IIIA
Non-Small Cell Lung Cancer: An East Asian Population-Based Study. Oncologist. 2012 Oct;17(10):1294-302. (*Co-corresponding authors)
62. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC. Pretreatment Epidermal Growth Factor Receptor (EGFR)
T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer. Journal of Clinical
Oncology 2012 Feb 01;30(4):433-40
63. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L,
Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W. Lung cancers with acquired
resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA. 2012 Jul
31;109(31):E2127-33.
64. Hsu CL, Chen KY, Shih JY, Ho CC, Yang CH, Yu CJ, Yang PC. Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and
prognostic factors. BMC Cancer. 2012 Jun 13;12:241.
65. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, Yu CJ. Genetic Polymorphism of XRCC1 Arg399Gln Is Associated With Survival in
Non-Small-Cell Lung Cancer Patients Treated With Gemcitabine/Platinum. J Thorac Oncol. 2012 Jun;7(6):973-981.
66. Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M. Randomized phase II trial of first-line treatment with
pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung
Cancer. 2012 Aug;77(2):346-52.
67. Chung KP, Wu SG, Wu JY, Yang JC, Yu CJ, Wei PF, Shih JY, Yang PC. Clinical Outcomes in Non-Small Cell Lung Cancers Harboring Different Exon 19
Deletions in EGFR. Clin Cancer Res. 2012 Jun 15;18(12):3470-7
68. Tsai TH, Wu SG, Chang YL, Wu CT, Tsai MF, Wei PF, Yang CH, Yu CJ, Yang PC, Shih JY. Effusion Immunocytochemistry as an Alternative Approach for the
Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma. J Thorac Oncol. 2012 Jun;7(6):993-1000.
69. Lin ZZ, Hsu C, Hu FC, Shao YY, Chang DY, Yang CH, Hong RL, Hsu CH, Cheng AL. Factors impacting prognosis prediction in BCLC stage C and
Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy. Oncologist. 2012 Jul ;17(7):970-7.
70. Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH, Yang PC. EML4-ALK translocation predicts better outcome in lung
adenocarcinoma patients with wild-type EGFR. J Thorac Oncol. 2012 Jan;7(1):98-104.
71. Chung KP, Huang YT, Chang YL, Yu CJ, Yang CH, Chang YC, Shih JY, Yang PC. Clinical significance of thyroid transcription factor-1 in advanced lung
adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment. Chest. 2012 Feb;141(2):420-8.
72. Kuo YH, Lin ZZ, Yang YY, Shao YY, Shau WY, Kuo RN, Yang JC and Lai MS. Survival of patients with small cell lung cancer in Taiwan. Oncology 2012 Jan
20;82(1):19-24
73. Girard N, Sima CS, Jackman DM, Sequist LV, Chen HQ, Yang JC, Ji HB, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G and Pao W.
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. European Respiratory J. 2012 Feb;39(2):366-72
74. Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T.
INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in
Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer. 2011 Oct 7;11:430.
75. Thongprasert S, Duffield E, Saijo N, Wu YL, Yang CH, Chu DT, Lia M, Chen YM, Kuo HP, Negoro S, Lam KC, Armour A, Magill R and Fukuoka M.
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with
advanced NSCLC. J Thorac Oncol 2011 Nov;6(11):1872-80.
76. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY and Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor
mutations of unknown clinical significance in non-small cell lung cancer. Clin Can Res. 2011 Jun 1;17(11):3812-21
77. Lin CC and Yang CH*. Optimal management of patients with nonsmall cell lung cancer and EGFR mutation. Drug 2011 Jan ;71(1)79-88
(*Corresponding
author) (review article)
78. de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, DeMarinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J and
Vansteenkiste J Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial
(ZEAL) J Clin Oncol 2011 Mar 10:29(8):1067-74
79. Chang TH, Tsai MF, Su KY, Wu SG, Huang CP, Yu SL, Yu YL, Lan CC, Yang CH, Lin SB, Wu CP, Shih JY, Yang PC. Slug confers resistance to the epidermal
growth factor receptor tyrosine kinase inhibitor Am J Respir Crit Care Med. 2011Apr ;183(8):1071-9
80. Wu JY, Shih JY, Chen KY, Yang CH, Yu CJ, Yang PC. Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for
epidermal growth factor receptor mutations. Medicine. 2011 May;90(3):159-67
81. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian
J, Qin Q, Scappaticci RA, Ricker JL, Garson DM, Soo RA. Phase II trial of Linifanib (ABT-869) in patients with advanced nonsmall cell lung cancer. J Thorac
Oncol. 2011Aug;6(8):1418-1425
82. Wu JY, Wu SG, Yang CH, Chang YL, Chang YC, Hsu YC, Shih JY, Yang PC. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of
EGFR mutation. Lung Cancer 2011May;72(2):205-12
83. Lee LJ, Chung CW, Chang YY, Lee YC, Yang CH, Liou Sh, Liu PH, Wang JD. Comparison of the quality of life between patients with non-small cell lung
cancer and healthy controls. Qual Life Res 2011 Apr ;20(3):415-23
84. Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ and Yang PC. Thymidylate synthase and dihydrofolate reductase expression in nonsmall cell
lung cancer carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 2011 Oct;74(1):132-8.
85. Lin ZZ and Yang CH*. Current Roles and Future Perspectives of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell
Lung Cancer. Eur J Clin Med Oncol 2011 March online publish (*Corresponding author) (Review article) (Non-SCI)
86. Wu SG, Yang CH, Yu CJ, Lee JH, Hsu YC, Chang YL, Shih JY and Yang PC. Good response to pemetrexed in patients of lung adenocarcinoma with epidermal
growth factor receptor (EGFR) mutations. Lung Cancer 2011 Jun;72(3):333-9
87. Sequist LV and Yang CH. A randomized phase III trial of BIBW 2992 versus chemotherapy as first-line treatment for stage IIIB/IV adenocarcinoma of the lung
harboring and epidermal growth factor receptor-activating mutation. Community Oncology 2010 Jul;7:1-4 (Non-SCI)
88. Lin CC, Hsu HH, Sun CT, Shih JY, Lin ZZ, Yu CJ, Chen GG, Hsin MK, Lam KC, Leung L, Yang CH* and Mok T. Chemotherapy response in East Asian
non-small cell lung cancer patients harboring wild type or activating mutation of epidermal growth factor receptors Journal of Thoracic Oncology 2010 Sep;
5(9): 1424-9 (*corresponding author)
89. Wu JY, Yang CH, Hsu YC, Yu CJ, Chang SH, Shih JY, Yang PC. Use of cetuximab after failure of gefitinib in patients with advanced non-small cell lung cancer.
Clin Lung Cancer. 2010 Jul 1;11(4):257-63.
90. Shao YY, Lin CC, Yang CH*. Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. Discov Med 2010 Jun;9(49):538-45
(*corresponding author)
91. Shao YY, Hu FC, Liang JT, Chiu WT, Cheng AL, Yang CH*. Characteristics and risk factors of oxaliplatin-related hypersensitivity reaction. J Formos Med
Assoc 2010 May;109(5):362-8 (*corresponding author)
92. Lee JH, Yu CJ, Chen KY, Shih JY, Lin YL, Yang CH*. Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer. J Formos Med
Assoc 2010 May ;109(5):338-44 (*corresponding author)
93. Chen KY, Chen JH, Shih JY, Yang CH, Yu CJ, Yang PC. Octagenarians with advanced non-small cell lung cancer treatment modalities, survival and prognostic
factors. Journal of Thoracic Oncology 2010 Jan;5(1):82-9
94. Cho BC, Kim JH, Soo RA and Yang CH*. The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced
Non-Small Cell Lung Cancer Yonsei Med J 2010 Jan ; 51(1):1-8 (review) (*corresponding author)
95. Wu JY, Shih JY, Yang CH, Chen KY, Ho CC, Yu CJ, Yang PC. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.
Int J Cancer 2010 Jan;126(1):247-55
96. Wu JY, Yu CJ, ShihJY, Yang CH and Yang PC. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell
lung cancer. Lung Cancer 2010 Mar;67(3):348-54
97. Huang CT, Yen RF, Cheng ME, Hsu YC, Wei PF, Tsai YJ, Tsai MF, Shih JY, Yang CH, Yang PC. Correlation of F-18-flurodeoxyglucose-positron emission
tomography maximal standardization uptake value and EGFR mutations in advanced lung adenocarcinoma. Medical Oncology, 2010 Mar ;27(1):9-15